Business, energy, technology, markets and global industry news from Business News Today

China

PharmaDeviceNews China
Rani Therapeutics and PegBio are evaluating the RaniPill platform for oral delivery of obesity and metabolic disease therapies now administered by injection. Representative image.
Pharma & Biotech

How Rani Therapeutics could convert PegBio’s injectable metabolic drugs into oral therapies

Rani Therapeutics Holdings, Inc. and PegBio Co., Ltd. have formed a research and development collaboration to evaluate whether several injectable obesity and metabolic disease candidates can be delivered through Rani Therapeutics’ swallowable RaniPill platform. The partners plan to screen oral formulations, complete preclinical development and select the most promising programmes for possible advancement into human

Read More
Hansoh Pharmaceutical Group’s Ris-Rez delivers an overall survival benefit in the Phase 3 ARTEMIS-008 trial for advanced small-cell lung cancer. Representative image.
Pharma & Biotech

Hansoh Pharma’s Ris-Rez improves survival in Phase 3 small-cell lung cancer trial

Hansoh Pharmaceutical Group Co., Ltd. has reported that risvutatug rezetecan, also known as Ris-Rez or HS-20093, significantly improved overall survival in the pivotal Phase 3 ARTEMIS-008 trial involving Chinese patients with advanced or relapsed small-cell lung cancer following platinum-based treatment. The B7-H3-directed antibody-drug conjugate was compared with topotecan and also produced a consistent benefit in

Read More
MindRank AI raises $52 million to advance its artificial intelligence drug discovery platform and Phase 3 oral GLP-1 candidate MDR-001 in China. Representative image.
Pharma & Biotech

MindRank backs Phase 3 oral GLP-1 programme with $52m Series B funding

MindRank AI Ltd. has completed a $52 million Series B financing to advance its artificial intelligence-led drug research platform and a clinical pipeline headed by MDR-001, an oral small-molecule glucagon-like peptide-1 receptor agonist already in Phase 3 development in China. The Hangzhou-based biotechnology company said the financing was led by a group of institutional and

Read More
Representative image: A dermatologist discusses plaque psoriasis treatment with a patient, reflecting Akeso’s gumokimab approval and the intensifying IL-17 biologics race in China’s autoimmune disease market.
Pharma & Biotech

Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race

Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.

Read More
Representative image of Alzheimer’s disease treatment and market analysis, highlighting how Eisai’s Leqembi sales simulation could shape BioArctic’s royalty outlook, investor sentiment and the commercial future of anti-amyloid therapies.
Pharma & Biotech

Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it

Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.

Read More
Pharma & Biotech

Lupin just cracked China with a flu drug. Why investors may want to look closer

Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.

Read More
Representative image of topical plaque psoriasis treatment and China market expansion, illustrating LEO Pharma’s Enstilar approval as the company targets growth in the world’s largest psoriasis patient market.
Pharma & Biotech

LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?

LEO Pharma has won China approval for Enstilar in plaque psoriasis. Read what it means for competition, access, and dermatology growth.

Read More
Pharma & Biotech

Mazdutide shows weight loss efficacy in Chinese teens: Phase 1b results raise hopes for approval

Innovent Biologics has reported that mazdutide, its dual GLP-1 and glucagon receptor agonist, achieved statistically significant reductions in both body mass index and weight in Chinese adolescents with obesity during a 12-week Phase 1b clinical trial. The trial met its primary endpoint, demonstrated a favorable safety profile, and paves the way for a Phase 3

Read More